Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1995-01-09
2002-06-11
Low, Christopher S. F. (Department: 1653)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S471000, C435S476000, C435S069100, C435S320100, C435S252300, C435S252330, C435S091400, C435S091100, C435S091410, C536S023100, C536S023400, C536S023200, C536S023500, C536S023510, C536S023520, C536S024100, C536S023700, C536S024200
Reexamination Certificate
active
06403336
ABSTRACT:
This invention relates to a new process for the production of &agr;-human atrial natriuretic polypeptide (hereinafter referred to as the abbreviation “&agr;-hANP”) by recombinant DNA technology. More particularly, it relates to a new process for the production of &agr;-hANP by recombinant DNA technology, to chemically synthesized genes for &agr;-hANP and protective peptide-fused &agr;-hANP and to a corresponding recombinant vector and transformant comprising the same.
The &agr;-hANP is a known polypeptide having a diuretic, natriuretic, vasorelaxant and antihypertensive activities Therefore, it may be useful in clinical treatment of hypertension as antihypertensive diuretic agent and has the following structure:
(Cf. Biochemical and Biophysical Research Communications Vol.118, page 131 (1984)).
The inventors of this invention have newly created a process for the production of &agr;-hANP by recombinant DNA technique using an expression vector comprising a synthetic gene encoding the amino acid sequence (I) of &agr;-hANP. According to this process, &agr;-hANP can be obtained in high yield.
This invention provide a process for the production of &agr;-hANP by (1) culturing a microorganism transformed with an expression vector comprising a synthetic gene encoding an amino acid sequence of a protective peptide-fused &agr;-hANP in a nutrient medium, (2) recovering the protective peptide-fused &agr;-hANP from the cultured broth and (3) removing the protective peptide part of the protective peptide-fused &agr;-hANP.
In the above process, particulars of which are explained in more detail as follows.
The microorganism is a host cell and may include bacteria, fungi, cultured human and animal cells and cultured plant cells. Preferred examples of the microorganism may include bacteria especially a strain belonging to the genus Escherichia (e.g.
E. coli
HB101 (ATCC 33694),
E. coli
294 (ATCC 31446),
E. coli
(1776) (ATCC 31537), etc).
The expression vector is usually composed of DNA having at least a promoter-operater region, initiation codon, synthetic protective peptide gene, synthetic &agr;-hANP gene, termination codon(s) and replicatable unit.
The promoter-operater region comprises promoter, operater and Shine-Dalgarno(SD) sequence (e.g. AAGG, etc.). The distance between SD sequence and initiation codon is preferably 8-12 b.p. and in the most preferable case as shown in the working Examples mentioned below, the distance between SD sequence and initiation codon (ATG) is 11 b.p. Examples of the promoter-operater region may include conventionally employed promoter-operater region (e.g. lactose-operon, PL-promoter, trp-promoter, etc.) as well as synthetic promoter-operater region. Preferred examples of the promoter-operater region are synthetic trp promoter I, II and III which were newly synthesized by the inventors of this invention and DNA sequences thereof are shown in
FIG. 1
,
2
and
3
, respectively. In the process,there may be used 1-3 consecutive promoter-operater region(s) per expression vector.
Preferred initiation codon may include methionine codon (ATG).
The protective peptide gene may include DNA sequence corresponding to any of peptide or protein which is capable of forming a fused protein with &agr;-hANP and inhibiting undesired degradation of the fused protein in the host cell or the cultured broth. One of preferred examples is “peptide Cd gene” linked to “LH protein gene” (hereinafter “the peptide Cd gene linked to LH protein gene” is referred to as “peptide CLa gene”), DNA sequence of which is shown in FIG.
4
.
The DNA sequence of &agr;-hANP gene is designed from the amino acid sequence of &agr;-hANP, subjected to a number of specific non-obvious criteria. Preferred example of DNA sequence of &agr;-hANP gene is shown in FIG.
5
. In the working Examples as mentioned below, between the &agr;-hANP gene and the protective peptide gene, a DNA sequence encoding amino acid lysine is inserted, with the purpose of Achromobacter protease I digestion at the junction of the fused protein.
The termination codon(s) may include conventionally employed termination codon (e.g. TAG, TGA, etc.).
The replicatable unit is a DNA sequence capable of replicating the whole DNA sequence belonging thereto in the host cells and may include natural plasmid, artificially modified plasmid (e.g. DNA fragment prepared from natural plasmid) and synthetic plasmid and preferred examples of the plasmid may include plasmid pBR 322 or artificially modified thereof (DNA fragment obtained from a suitable restriction enzyme treatment of pBR 322). The replicatable unit may contain natural or synthetic terminator (e.g. synthetic fd phage terminator, etc.).
Synthetic preparation of promoter-operater region, initiation codon,protective peptide gene, &agr;-hANP gene and termination codon can be prepared in a conventional manner as generally employed for the preparation of polynucleotides.
The promoter-operater region, initiation codon, protective peptide gene, &agr;-hANP gene and termination codon(s) can consecutively and circularly be linked with an adequate replicatable unit (plasmid) together, if desired using an adequate DNA fragment(s) (e.g. linker, other restriction site , etc.) in a conventional manner (e.g. digestion with restriction enzyme, phosphorylation using T4 polynucleotide kinase, ligation using T4 DNA-ligase) to give an expression vector.
The expression vector can be inserted into a microorganism (host cell). The insertion can be carried out in a conventional manner (e.g. transformation, microinjection, etc.) to give a transformant.
For the production of &agr;-hANP in the process of this invention, thus obtained transformant comprising the expression vector is cultured in a nutrient medium.
The nutrient medium contains carbon source(s) (e.g. glucose, glycerine, mannitol, fructose, lactose, etc.) and inorganic or organic nitrogen source(s) (ammonium sulfate, ammonium chloride, hydrolysate of casein, yeast extract, polypeptone, bactotrypton, beef extracts, etc.). If desired, other nutritious sources (e.g. inorganic salts (e.g. sodium or potassium biphosphate, dipotassium hydrogen phosphate, magnesium chloride, magnesium sulfate, calcium chloride), vitamins (e.g. vitamin B1), antibiotics (e.g. ampicillin), etc.) may be added to the medium.
The culture of transformant may generally be carried out at pH 5.5-8.5 (preferably pH 7-7.5) and 18-40° C. (preferably 25-38° C.) for 5-50 hours.
Since thus produced protective peptide-fused &agr;-hANP generally exists in cells of the cultured transformant, the cells are collected by filtration or centrifuge, and cell wall and/or cell membrane thereof is destroyed in a conventional manner (e.g. treatment with super sonic waves and/or lysozyme, etc.) to give debris. From the debris, the protective peptide-fused &agr;-hANP can be purified and isolated in a conventional manner as generally employed for the purification and isolation of natural or synthetic proteins (e.g. dissolution of protein with an appropriate solvent (e.g. 8M aqueous urea, 6M guanidine, etc.), dialysis, gel filtration, column chromatography, high performance liquid chromatography, etc.).
The &agr;-hANP can be prepared by cleaving the protective peptide-fused &agr;-hANP in the presence of an appropriate protease (e.g. Achromobacter Protease I (AP I), etc.) treatment or chemical method (e.g. treatment with cyanogen bromide). In the case where C-terminal of the protective peptide is lysine, there can preferably be employed treatment with API. Although API is a known enzyme (Cf. Biochim. Biophys. Acta., 660, 51 (1981)), it has never been reported that fused proteins prepared via recombinant DNA technology can preferably be cleaved by the treatment with API. This method may preferably be employed for cleaving a fused protein composed of peptides having a lysine between a protective peptide and a target peptide having no lysine in its molecule.
The cleavage of the fused protein may be carried out at pH 5-10 and 20-40° C. (preferably 35-40° C.) for 2-15 hours in an aqueous solution (e.g. buffer solut
Ishii Yoshinori
Niwa Mineo
Saito Yoshimasa
Ueda Ikuo
Yamada Hisashi
Fujisawa Pharmaceutical Co. Ltd.
Low Christopher S. F.
LandOfFree
Process for the production of &agr;-human atrial natriuretic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the production of &agr;-human atrial natriuretic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the production of &agr;-human atrial natriuretic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2927553